According to Zhitong Finance APP, on November 22, 华领医药-B (02552) announced that it has issued a written notice to Bayer HealthCare Ltd., expressing its intention to transfer the commercialization responsibility of its pioneering glucose kinase activator,华堂宁, for the treatment of type 2 diabetes in china, effective January 1, 2025. To achieve the transition, the company has the right and plans to terminate the agreement starting from January 1, 2025. From the date of this announcement until the termination effective date, Bayer and the company will continue to fulfill their obligations under the agreement and commit to initiating a friendly, patient-centered transition plan. To support the continued commercial sales of华堂宁 in china, the company may seek other potential partners for its commercialization in China.

It is understood that 华领医药 signed a strategic cooperation agreement with Bayer on August 17, 2020, regarding华堂宁 (dorzagliatin tablets). As of now,华领医药 has received milestone payments from Bayer totaling 1.5 billion yuan. This fund will be used to establish its own sales team and expand overseas business, further enhancing华领医药's competitiveness in the global diabetes treatment field. Previously, the cooperation model between华领医药 and Bayer was a 50-50 profit sharing, which was sufficient to cover the costs of establishing its sales team, while also bringing additional profits to the company.

Since华堂宁 (dorzagliatin tablets) entered the national medical insurance drug list, it has established a strong hospital channel network in china, covering over 2,000 hospitals, particularly dense in hospitals in cities like peking, tianjin, and shanghai. This extensive market coverage not only provides华领医药 with a solid market foundation but also lays a good groundwork for the upcoming volume sales under medical insurance. Sales after the volume release will further enhance the market penetration of华堂宁, bringing benefits to more type 2 diabetes patients.

In addition, dorzagliatin is rapidly increasing its production capacity and accelerating its entry into hospitals and pharmacies across the country to benefit more patients. As the number of users continues to grow, the safety of华堂宁 has been well verified, and its economic and social benefits have also significantly improved, instilling confidence in华领医药's future development.